ArticleCancer2025
Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo evaluate the efficacy, safety, and predictive biomarker of a third-generation tyrosine kinase inhibitor (3G-TKI; ponatinib or olverembatinib) combined with azacitidine in chronic myeloid leukemia (CML) in myeloid blast phase.
methodsWe conducted a single-center, prospective study combining 3G-TKI with azacitidine in 28-day cycles. The primary end point was a major hematologic response (MaHR) by cycle 2. The trial is registered in Chinese Clinical Trial Registry (ChiCTR2200055887)
resultsIn total, 37 patients were studied. The median follow-up was 30 months (interquartile range, 24-40 months). Twenty-five patients achieved a MaHR by cycle 2, 30 returned to chronic phase. Ten patients underwent transplantation. The patients who underwent transplantation had higher 3-year probability of survival compared with nontransplanted patients (50%; [95% confidence interval (CI), 9%-37%] versus 18% [95% CI, 3%-33%]; p = .01). The regimen was well tolerated. In adjusted logistic/Cox regression analyses, KRAS mutation was significantly associated with a lower MaHR rate (odds ratio, 0.1; 95% CI, 0-0.8; p = .03), worse progression-free survival (PFS; hazard ratio [HR], 3.1; 95% CI, 1.1-8.6; p = .04), and worse survival (HR, 8.2; 95% CI, 2.5-26.8; p < .001); PTPN11 mutation was associated with worse PFS (HR, 5.1; 95% CI, 1.2-22.2; p = 0.03) and worse survival (HR, 9.6; 95% CI, 2.2-41.5; p = .002); and increasing numbers of non-ABL1 mutations were associated with worse PFS (HR, 1.2; 95% CI, 1.0-1.3; p = .04). Transcriptomic analysis revealed that patients who did not achieve a MaHR experienced activation of cancer-, metabolism-, oxidative phosphorylation-related pathways. The KRAS signaling pathway was significantly activated in patients who lost MaHR during treatment.
conclusions3G-TKI with azacitidine is an effective and safe therapy providing more chance to receive a transplantation for CML in myeloid blast phase. Potential biomarkers associated with outcomes were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.